Squarepoint Ops LLC Makes New $3.74 Million Investment in ICU Medical, Inc. $ICUI

Key Points

• Squarepoint Ops LLC acquired a new 25,540-share stake in ICU Medical during the second quarter, valued at approximately $3.74 million. Institutional investors and hedge funds collectively own 96.1% of the company.
• Analyst sentiment remains generally positive, with ICU Medical carrying a consensus “Moderate Buy” rating and an average price target of $192.80. Piper Sandler and BTIG Research raised their targets to $195 and $200, respectively, while some firms downgraded the stock to “Hold” or “Market Perform.”
• ICU Medical exceeded quarterly earnings expectations, reporting $2.37 in EPS versus the $1.91 consensus and revenue of $547.88 million. However, insiders sold 21,830 shares worth roughly $3.91 million over the past 90 days, and the stock opened at $156.48, down 0.5%.

Squarepoint Ops LLC bought a new stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 25,540 shares of the medical instruments supplier's stock, valued at approximately $3,744,000. Squarepoint Ops LLC owned approximately 0.10% of ICU Medical as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Allworth Financial LP acquired a new position in shares of ICU Medical during the 2nd quarter valued at about $26,000. Hilton Head Capital Partners LLC acquired a new stake in ICU Medical during the fourth quarter worth about $32,000. Public Employees Retirement System of Ohio acquired a new stake in ICU Medical during the second quarter worth about $51,000. Covestor Ltd raised its stake in ICU Medical by 22.1% during the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 126 shares during the period. Finally, Rockefeller Capital Management L.P. raised its stake in ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier's stock worth $117,000 after purchasing an additional 146 shares during the period. 96.10% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ICUI has been the subject of several analyst reports. Zacks Research cut shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Sanford C. Bernstein lowered shares of ICU Medical to a "market perform" rating in a research report on Monday, June 15th. Piper Sandler upped their price objective on ICU Medical from $163.00 to $195.00 and gave the company an "overweight" rating in a report on Friday, August 7th. BTIG Research increased their price objective on ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Finally, Wall Street Zen raised ICU Medical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $192.80.

Insider Buying and Selling

In other news, VP Daniel Woolson sold 5,417 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $181.33, for a total transaction of $982,264.61. Following the sale, the vice president owned 17,062 shares of the company's stock, valued at approximately $3,093,852.46. This represents a 24.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elisha W. Finney sold 378 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total transaction of $68,977.44. Following the completion of the transaction, the director directly owned 4,871 shares of the company's stock, valued at approximately $888,860.08. The trade was a 7.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 21,830 shares of company stock worth $3,905,003 over the last 90 days. 2.10% of the stock is owned by insiders.

ICU Medical Stock Down 0.5%

NASDAQ:ICUI opened at $156.48 on Friday. ICU Medical, Inc. has a 52 week low of $112.50 and a 52 week high of $192.85. The stock's fifty day moving average is $168.36 and its two-hundred day moving average is $145.22. The stock has a market capitalization of $3.91 billion, a price-to-earnings ratio of 132.61, a price-to-earnings-growth ratio of 1.98 and a beta of 0.75. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $0.46. The business had revenue of $547.88 million during the quarter, compared to analysts' expectations of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The company's revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Research analysts anticipate that ICU Medical, Inc. will post 7.19 EPS for the current year.

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices used in infusion therapy, critical care and oncology. Its product portfolio includes infusion pumps, IV administration sets, needle-free connectors, vascular access devices, patient monitoring equipment and related accessories designed to support the delivery of fluids and medications and the monitoring of patients in healthcare settings.

The company also provides products for the safe handling of hazardous drugs, including closed-system transfer devices used in oncology and pharmacy operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.